Transcriptomic signature of response to vedolizumab in patients with moderate-to-severe ulcerative colitis: Results from an international, multicentre, retrospective cohort study

被引：0
|
作者：
Linggi, B. [1 ]
Salas, A. [2 ,3 ]
Veny, M. [2 ,3 ]
Borowski, K. [4 ]
Silverberg, M. S. [4 ,5 ]
Milgrom, R. [4 ]
Stempak, J. [4 ]
Boland, B. [6 ]
Eckmann, L. [6 ]
Smith, M. I. [1 ]
Parker, C. E. [1 ]
Jairath, V. [1 ,7 ,8 ]
Teft, W. [1 ]
Vande Casteele, N. [1 ,6 ]
机构：
[1] Aliment Inc, Med Resesarch & Dev, London, ON, Canada
[2] Fundacio Recerca Clin Barcelona FRCB IDIBAPS Hosp, Inflammatory Bowel Dis Unit, Barcelona, Spain
[3] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inflammatory Bowel Dis Unit, Barcelona, Spain
[4] Sinai Hlth Syst, Zane Cohen Ctr Digest Dis, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Div Gastroenterol, Mt Sinai Hosp, Toronto, ON, Canada
[6] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[7] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
[8] Western Univ, Dept Med, London, ON, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP40
引用
收藏
页码：I71 / I71
页数：1
相关论文
共 50 条
  • [21] Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort study
    Konikoff, T.
    Yanai, H.
    Banai, H.
    Avni-Biron, I.
    Snir, Y.
    Broitman, L.
    Barkan, R.
    Checholin, L.
    Dotan, I.
    Ollech, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I463 - I464
  • [22] Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    Feagan, Brian G.
    Marano, Colleen
    Zhang, Hongyan
    Strauss, Richard
    Johanns, Jewel
    Adedokun, Omoniyi J.
    Guzzo, Cynthia
    Colombel, Jean-Frederic
    Reinisch, Walter
    Gibson, Peter R.
    Collins, Judith
    Jarnerot, Gunnar
    Rutgeerts, Paul
    GASTROENTEROLOGY, 2014, 146 (01) : 96 - +
  • [23] Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study
    Yoshimura, N.
    Okano, Soh
    Sako, Minako
    Takazoe, Masakazu
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S545 - S545
  • [24] Ustekinumab for the treatment o moderate to severe ulcerative colitis: a multicentre UK cohort study
    Honap, Sailish
    Al-Hillawi, Lulia
    Baillie, Samantha
    Bancil, Aaron
    Matini, Lawrence
    Lau, Rebecca
    Kok, Klaartje Bel
    Patel, Kamal
    Walsh, Alissa
    Irving, Peter M.
    Samaan, Mark A.
    FRONTLINE GASTROENTEROLOGY, 2022, 13 (06) : 517 - 523
  • [25] Long-Term Effectiveness and Safety of Ustekinumab Dose Escalation in Patients with Moderate-to-Severe Ulcerative Colitis: A Multicenter Retrospective Cohort Study
    van Lierop, Lisa M. A.
    Albino, Larissa
    Rosentreter, Ryan
    Thomas, Pepijn W. A.
    Lu, Cathy
    Siffledeen, Jesse
    Kroeker, Karen I.
    Ma, Christopher
    Peerani, Farhad
    Halloran, Brendan P.
    Baumgart, Daniel C.
    Dieleman, Levinus A.
    Du, Lillian
    Hoentjen, Frank
    Wong, Karen
    DIGESTIVE DISEASES AND SCIENCES, 2025,
  • [26] Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
    Katsuyoshi Matsuoka
    Tadakazu Hisamatsu
    Yohei Mikami
    Takayuki Yamamoto
    Satoshi Motoya
    Shinichiro Shinzaki
    Ryuichi Iwakiri
    Kenkichi Sugiura
    Kunihiko Nishimura
    Mika Kajita
    Jovelle L. Fernandez
    Advances in Therapy, 2023, 40 : 2902 - 2914
  • [27] Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
    Matsuoka, Katsuyoshi
    Hisamatsu, Tadakazu
    Mikami, Yohei
    Yamamoto, Takayuki
    Motoya, Satoshi
    Shinzaki, Shinichiro
    Iwakiri, Ryuichi
    Sugiura, Kenkichi
    Nishimura, Kunihiko
    Kajita, Mika
    Fernandez, Jovelle L.
    ADVANCES IN THERAPY, 2023, 40 (06) : 2902 - 2914
  • [28] Biologics for the treatment of moderate-to-severe ulcerative colitis in pediatric patients
    Albenberg, Lindsey G.
    Mamula, Petar
    Kelsen, Judith R.
    PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2012, 3 : 51 - 58
  • [29] Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
    Bamias, Giorgos
    Kokkotis, Georgios
    Gizis, Michalis
    Kapizioni, Christina
    Karmiris, Konstantinos
    Koureta, Evgenia
    Kyriakos, Nikolaos
    Leonidakis, Georgios
    Makris, Konstantinos
    Markopoulos, Panagiotis
    Michalopoulos, Georgios
    Michopoulos, Spyridon
    Papaconstantinou, Ioannis
    Polymeros, Dimitrios
    Siakavellas, Spyros, I
    Triantafyllou, Konstantinos
    Tsironi, Eftychia
    Tsoukali, Emmanouela
    Tzouvala, Maria
    Viazis, Nikos
    Xourafas, Vassileios
    Zacharopoulou, Eirini
    Zampeli, Evanthia
    Zografos, Konstantinos
    Papatheodoridis, George
    Mantzaris, Gerasimos
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (03) : 1007 - 1017
  • [30] Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
    Giorgos Bamias
    Georgios Kokkotis
    Michalis Gizis
    Christina Kapizioni
    Konstantinos Karmiris
    Evgenia Koureta
    Nikolaos Kyriakos
    Georgios Leonidakis
    Konstantinos Makris
    Panagiotis Markopoulos
    Georgios Michalopoulos
    Spyridon Michopoulos
    Ioannis Papaconstantinou
    Dimitrios Polymeros
    Spyros I. Siakavellas
    Konstantinos Triantafyllou
    Eftychia Tsironi
    Emmanouela Tsoukali
    Maria Tzouvala
    Nikos Viazis
    Vassileios Xourafas
    Eirini Zacharopoulou
    Evanthia Zampeli
    Konstantinos Zografos
    George Papatheodoridis
    Gerasimos Mantzaris
    Digestive Diseases and Sciences, 2022, 67 : 1007 - 1017
12345